Stocksigma LogoStocksigma Logo

Accretion Pharmaceuticals Delivers Robust H1 FY27 Growth with PAT Surging 72.63% YoY

Accretion Pharmaceuticals reported a strong performance for H1 FY27, with revenue from operations growing 25.83% YoY to ₹55.04 crore

Accretion Pharmaceuticals Delivers Robust H1 FY27 Growth with PAT Surging 72.63% YoY

Accretion Pharmaceuticals Ltd · Investor Presentation · 03 Nov 2026, 10:55 pm

Accretion Pharmaceuticals Delivers Robust H1 FY27 Growth with PAT Surging 72.63% YoY Accretion Pharmaceuticals reported a strong performance for H1 FY27, with revenue from operations growing 25.83% YoY to ₹55.04 crore. EBITDA jumped 72.28% YoY to ₹12.37 crore as EBITDA margin expanded 606 bps to 22.48%. Net profit surged 72.63% YoY to ₹8.20 crore, expanding PAT margins by 403 bps to 14.90%. Export contribution doubled to 18.15% from 9.16% in H1 FY26. Growth was driven by an improved product mix, capacity additions, and expanding international presence across 30+ countries, alongside ongoing CAPEX for facility expansion.

Original exchange filing (PDF)

More announcements from Accretion Pharmaceuticals Ltd

All Accretion Pharmaceuticals Ltd announcements